Zobrazeno 1 - 10
of 241
pro vyhledávání: '"EZH2 inhibitor"'
Publikováno v:
PeerJ, Vol 12, p e18656 (2024)
Acute myeloid leukemia (AML), a malignant disease of the bone marrow, is characterized by the clonal expansion of myeloid progenitor cells and a block in differentiation. The high heterogeneity of AML significantly impedes the development of effectiv
Externí odkaz:
https://doaj.org/article/eb588253a2d44ee0b52fa704f3c9e2e6
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-13 (2023)
Abstract Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methylt
Externí odkaz:
https://doaj.org/article/cb1c766483824a73abfef4593e51b6f1
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-13 (2023)
Abstract Background Advances in understanding of cancer biology, genomics, epigenomics, and immunology have resulted in development of several therapeutic options that expand cancer care beyond traditional chemotherapy or radiotherapy, including indi
Externí odkaz:
https://doaj.org/article/bc086a5c0214438896a2400f8e952657
Autor:
Kunhong Deng, Yi Zou, Chan Zou, Hong Wang, Yuxia Xiang, Xiaoyan Yang, Shuang Yang, Chang Cui, Guoping Yang, Jie Huang
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1431-1440 (2023)
Abstract Background SHR2554, a novel oral Enhancer of Zeste Homolog 2 inhibitor, shows broad‐spectrum anti‐tumor efficacy in preclinical studies. As SHR2554 is mainly metabolized by CYP3A4, it is helpful to conduct research on the effects of itra
Externí odkaz:
https://doaj.org/article/24747840d0af44f7a3529aacfe5b5c43
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alan Z. Skarbnik, Krish Patel
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Follicular lymphoma (FL) is the second most common lymphoma in the United States and is characterized by a variable clinical course, disease heterogeneity, and a relapse-and-remittance pattern historically accompanied by successive shortening of clin
Externí odkaz:
https://doaj.org/article/5e111dca403e4a0fbead160cfaf827df
Autor:
Giulia Pinton, Zhuo Wang, Cecilia Balzano, Sara Missaglia, Daniela Tavian, Renzo Boldorini, Dean A. Fennell, Martin Griffin, Laura Moro
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/9416eee38cb7406f8341ad38e92f3863
Autor:
Chen Li, Jiagui Song, Zhengyang Guo, Yueqing Gong, Tengrui Zhang, Jiaqi Huang, Rui Cheng, Xiaotong Yu, Yanfang Li, Li Chen, Xiaojuan Ma, Yan Sun, Yan Wang, Lixiang Xue
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
EZH2 inhibitors (EZH2i), a class of small-molecule inhibitors that target EZH2 to exert anti-tumor functions, have just been approved by the US Food and Drug Administration (FDA) in treatment of adults and adolescents with locally advanced or metasta
Externí odkaz:
https://doaj.org/article/03a344b3724248ed9d0e0cde3a386412
Autor:
Hao Gong, Yongwen Li, Yin Yuan, Weiting Li, Hongbing Zhang, Zihe Zhang, Ruifeng Shi, Minghui Liu, Chao Liu, Chen Chen, Hongyu Liu, Jun Chen
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-18 (2020)
Abstract Background Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In traditional anti-cancer therapy, epidermal growth factor receptor (EGFR)-tyrosine k
Externí odkaz:
https://doaj.org/article/3c125cd416314c3a9708bd0058b8078a